Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ProPhase Labs Temettü

Temettü kriter kontrolleri 0/6

ProPhase Labs şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

Ödeme oranı

Sektör ortalama getirisi	2.2%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	US$0.300
Hisse başına kazanç	-US$1.38
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Recent updates

Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Jul 03

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Mar 04

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Jan 09

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Sep 21

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

Aug 11

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Apr 07

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Jul 21

ProPhase Labs: A Stellar Quarter And Another Special Dividend

May 16

ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 08

ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely

Mar 23

Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt

Nov 30

As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit

Oct 20

Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)

Jul 22

ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants

Jun 28

Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More

May 14

ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing

May 06

A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)

Apr 12

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: PRPH şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: PRPH şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

ProPhase Labs Piyasaya Karşı Temettü Getirisi

PRPH temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (PRPH)	0%
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Pharmaceuticals)	2.2%
Analist tahmini (PRPH) (3 yıla kadar)	n/a

Önemli Temettü: PRPH şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, PRPH şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: PRPH US piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: PRPH herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

ProPhase Labs Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Upcoming dividend of US$0.30 per share

ProPhase Labs, Inc. Declares Special Cash Dividend, Payable June 3, 2022

Upcoming dividend of US$0.30 per share

ProPhase Labs, Inc. Declares Special Cash Dividend, Payable on March 10, 2022

Upcoming dividend of US$0.30 per share

Prophase Labs, Inc. Declares Special Cash Dividend on Its Common Stock, Payable on June 3, 2021

Recent updates

ProPhase Labs Receives Non-Compliance Notice from Nasdaq Regarding Listing Rule 5605(c)(2)(A)

ProPhase Labs, Inc. announced delayed 10-Q filing

ProPhase Labs, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Price target decreased by 7.5% to US$18.50

Insufficient new directors

ProPhase Labs, Inc., Annual General Meeting, Jun 20, 2024

ProPhase Labs, Inc. to Report Q1, 2024 Results on May 09, 2024

ProPhase Labs, Inc. Unveils Project ZenQ-AI

ProPhase Labs, Inc. announced delayed annual 10-K filing

ProPhase Labs, Inc. to Report Fiscal Year 2023 Results on Mar 15, 2024

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Prophase Labs, Inc. Announces Important Developments in the Company’s Efforts to Commercialize Its Novel Be-Smart Esophageal Cancer Diagnostic Test

ProPhase Labs, Inc. Announces Preliminary Positive Results for Dietary Supplement Equivir

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Consensus revenue estimates fall by 16%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

ProPhase Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Consensus EPS estimates fall by 46%

New minor risk - Market cap size

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

First quarter 2023 earnings released: EPS: US$0.033 (vs US$0.81 in 1Q 2022)

Investor sentiment deteriorates as stock falls 15%

ProPhase Labs, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Investor sentiment deteriorates as stock falls 17%

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

Consensus estimates of losses per share improve by 19%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs, Inc. to Report Q1, 2023 Results on May 11, 2023

Investor sentiment improves as stock rises 18%

Price target increased by 13% to US$17.00

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 17%

ProPhase Labs, Inc. Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy

Chairman & CEO exercised options and sold US$2.0m worth of stock

ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly

Chairman & CEO exercised options and sold US$2.8m worth of stock

ProPhase Labs, Inc. (NasdaqCM:PRPH) acquired World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.6 million.

ProPhase Labs, Inc. Announces Executive Changes

ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for approximately $4.5 million.

Consensus forecasts updated

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% undervalued after recent price drop

ProPhase Labs, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment improved over the past week

Chairman & CEO exercised options and sold US$3.1m worth of stock

ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential

ProPhase Labs, Inc. Announces Resignation of Bill White as Chief Financial Officer

Consensus EPS estimates increase by 49%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs Q2 2022 Earnings Preview

ProPhase Labs, Inc. to Report Q2, 2022 Results on Aug 11, 2022

ProPhase Labs, Inc. (NasdaqCM:PRPH) announces an Equity Buyback for $6 million worth of its shares.

We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt

Investor sentiment deteriorated over the past week

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Price target increased to US$14.50

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Insufficient new directors

Chairman & CEO exercised options and sold US$1.8m worth of stock

Investor sentiment improved over the past week

Price target decreased to US$13.00

Upcoming dividend of US$0.30 per share

ProPhase Labs: A Stellar Quarter And Another Special Dividend